Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Healthy Participants Clinical Trial

Official title:

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05511025
• Other study ID #: D8750C00001
• Status: Completed
• Phase: Phase 1
• Start date: September 20, 2022
• Est. completion date: December 19, 2023

Study information

• Verified date: December 2023
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study in healthy male and female participants of non-childbearing potential who are overweight or obese.

Description:

The study will comprise of:

• A Screening Period of maximum 28 days.

• A Treatment Period during which participants will be resident at the Clinical Unit from three days before (Day -3 ) Investigational Medicinal Product (IMP) administration (Day 1) until at least 4 days (96 hours) after IMP administration, participants will then be discharged on the morning of Day 5.

• Weekly outpatient visits on Days 8, 15, 22, 29, and 36 for blood sample collection, Electrocardiogram (ECGs), and adverse events (AE) recording.

• A Follow-up Visit 6 weeks (Day 43) after the last IMP dose.

Furthermore, 3 dose levels of AZD6234 for Subcutaneous (SC) administration (Cohorts 1 to 3) and one dose level for Intravenous (IV) administration (Cohort 4) are planned to be investigated in healthy participants who are overweight or obese. The IV cohort (Cohort 4) can begin in parallel or after Cohort 3. One dose level for SC administration is planned to be investigated in Japanese participants only (Cohort 5), and up to 3 additional dose levels for SC administration are planned to be investigated in healthy participants (Cohort 6 to 8). Depending on the findings, additional (optional) dose level cohorts may be added at the discretion of the Sponsor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 54
• Est. completion date: December 19, 2023
• Est. primary completion date: December 19, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures.

• Healthy male and female participants aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.

• Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of non childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria:

(i) Post menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle stimulating hormone (FSH) levels in the post menopausal range.

(ii) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

• Have a body mass index (BMI) of 25 to 35 kg/m2 inclusive (at the time of screening) and weigh at least 50 kg.

For the Japanese cohort(s):

• Participant is a native of Japan; defined as having both parents and four grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.

• Have a BMI of 23 to 35 kg/m2 inclusive (at the time of screening) and weigh at least 50 kg.

Exclusion Criteria:

• History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study, including:

(i) Gastroparesis (or similar) requiring treatment, or (ii) Previous surgery of the upper gastrointestinal tract, or (iii) Cardiovascular disease, including but not limited to sick sinus syndrome, valvular disease, and cardiomyopathy, or (iv) Neuromuscular or neurogenic disease, or (v) Severe vitamin D deficiency < 12 ng/dL (as assessed by screening laboratory results or history), or (vi) Type 1 or type 2 diabetes mellitus.

• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.

• Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.

• Any laboratory values with the following deviations:

(i) Alanine aminotransferase > Upper limit of normal (ULN) (ii) Aspartate aminotransferase > ULN (iii) eGFR < 60 ml/min/1.73 m2 (calculated using the CKD EPI formula) (iv) White blood cell count < LLN (v) Hemoglobin < LLN (vi) Total calcium or corrected calcium/ionized calcium < LLN or > ULN

• Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

(i) Systolic Blood pressure (BP) < 90 mmHg or > 140 mmHg. (ii) Diastolic BP < 50 mmHg or > 90 mmHg. (iii) Heart rate < 55 or > 85 beats per minute (bpm)

• History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6234.

• Has received another new chemical entity (defined as a compound which has not been approved for marketing) within at least 30 days or 5 half-lives (whichever is longer) of the first administration of IMP in this study. The period of exclusion begins 30 days or 5 half-lives after the last visit in the previous study, whichever is the longest.

• Participants who are vegans or have medical dietary restrictions.

• Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Related Conditions & MeSH terms

• Healthy Participants
• Overweight

Intervention

Drug:
• AZD6234
Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
• Placebo
Participants will receive matching volumes of the placebo as a solution via SC or IV injection

Combination Product:
• Acetaminophen
Participants will receive a single dose of acetaminophen as part of a meal

Locations

Country	Name	City	State
United States	Research Site	Brooklyn	Maryland
United States	Research Site	Glendale	California

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with AEs and Serious Adverse Events(SAE)	The safety and tolerability of AZD6234 following subcutaneous and/or intravenous administration of single ascending doses in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Screening until Follow up (Day 43)
Secondary	Maximum observed plasma drug concentration (Cmax)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Area under the plasma concentration-time (AUClast)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Area under plasma concentration-time curve from zero to infinity (AUCinf)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Time to reach maximum observed concentration (tmax)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Terminal rate constant (?z)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Terminal elimination half-life (t½?z)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Total body clearance of drug from plasma (IV dosing only) (CL)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Apparent total body clearance of drug from plasma (SC dosing only) (CL/F)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Volume of distribution based on the terminal phase (IV dosing only) (Vz)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Apparent volume of distribution based on the terminal phase (SC dosing only) (Vz/F)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Dose-normalized AUClast (AUClast/D)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Dose-normalized AUCinf (AUCinf/D)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Dose-normalized Cmax (Cmax/D)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Time of last observed (quantifiable) concentration (tlast)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Secondary	Prevalence and incidence of anti-drug antibodies (ADAs) to AZD6234	The immunogenicity following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	Day 1, Day 15, Day 29 and at Follow up (Day 43)
Secondary	ADA titer	The immunogenicity following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy subjects, including Japanese subjects, who are overweight or obese will be assessed	Day 1, Day 15, Day 29 and at Follow up (Day 43)